86 related articles for article (PubMed ID: 38557494)
21. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.
Armandi A; Bugianesi E
Eur J Intern Med; 2024 Apr; 122():20-27. PubMed ID: 38262842
[TBL] [Abstract][Full Text] [Related]
22. Protective hepatocyte signals restrain liver fibrosis in metabolic dysfunction-associated steatohepatitis.
Steffani M; Geng Y; Pajvani UB; Schwabe RF
J Clin Invest; 2024 Apr; 134(7):. PubMed ID: 38557494
[TBL] [Abstract][Full Text] [Related]
23. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
[TBL] [Abstract][Full Text] [Related]
24. Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module.
Bendixen SM; Jakobsgaard PR; Hansen D; Hejn KH; Terkelsen MK; Bjerre FA; Thulesen AP; Eriksen NG; Hallenborg P; Geng Y; Dam TV; Larsen FT; Wernberg CW; Vijayathurai J; Scott EAH; Marcher AB; Detlefsen S; Grøntved L; Dimke H; Berdeaux R; de Aguiar Vallim TQ; Olinga P; Lauridsen MM; Krag A; Blagoev B; Ravnskjaer K
J Hepatol; 2024 Mar; 80(3):467-481. PubMed ID: 37972658
[TBL] [Abstract][Full Text] [Related]
25. Hepatocyte-specific CCAAT/enhancer binding protein α restricts liver fibrosis progression.
Yan T; Yan N; Xia Y; Sawaswong V; Zhu X; Dias HB; Aibara D; Takahashi S; Hamada K; Saito Y; Li G; Liu H; Yan H; Velenosi TJ; Krausz KW; Huang J; Kimura S; Rotman Y; Qu A; Hao H; Gonzalez FJ
J Clin Invest; 2024 Apr; 134(7):. PubMed ID: 38557493
[TBL] [Abstract][Full Text] [Related]
26. Found in translation-Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH).
Wang S; Friedman SL
Sci Transl Med; 2023 Oct; 15(716):eadi0759. PubMed ID: 37792957
[TBL] [Abstract][Full Text] [Related]
27. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
[TBL] [Abstract][Full Text] [Related]
28. Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin.
Gogate A; Belcourt J; Shah M; Wang AZ; Frankel A; Kolmel H; Chalon M; Stephen P; Kolli A; Tawfik SM; Jin J; Bahal R; Rasmussen TP; Manautou JE; Zhong XB
Pharmacol Rev; 2023 Dec; 76(1):49-89. PubMed ID: 37696583
[TBL] [Abstract][Full Text] [Related]
29. Macrophage-derived Osteopontin (SPP1) Protects From Nonalcoholic Steatohepatitis.
Han H; Ge X; Komakula SSB; Desert R; Das S; Song Z; Chen W; Athavale D; Gaskell H; Lantvit D; Guzman G; Nieto N
Gastroenterology; 2023 Jul; 165(1):201-217. PubMed ID: 37028770
[TBL] [Abstract][Full Text] [Related]
30. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.
Younossi ZM; Golabi P; Paik JM; Henry A; Van Dongen C; Henry L
Hepatology; 2023 Apr; 77(4):1335-1347. PubMed ID: 36626630
[TBL] [Abstract][Full Text] [Related]
31. Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis.
Filliol A; Saito Y; Nair A; Dapito DH; Yu LX; Ravichandra A; Bhattacharjee S; Affo S; Fujiwara N; Su H; Sun Q; Savage TM; Wilson-Kanamori JR; Caviglia JM; Chin L; Chen D; Wang X; Caruso S; Kang JK; Amin AD; Wallace S; Dobie R; Yin D; Rodriguez-Fiallos OM; Yin C; Mehal A; Izar B; Friedman RA; Wells RG; Pajvani UB; Hoshida Y; Remotti HE; Arpaia N; Zucman-Rossi J; Karin M; Henderson NC; Tabas I; Schwabe RF
Nature; 2022 Oct; 610(7931):356-365. PubMed ID: 36198802
[TBL] [Abstract][Full Text] [Related]
32. Understanding the cellular interactome of non-alcoholic fatty liver disease.
Wallace SJ; Tacke F; Schwabe RF; Henderson NC
JHEP Rep; 2022 Aug; 4(8):100524. PubMed ID: 35845296
[TBL] [Abstract][Full Text] [Related]
33. FDA approves fifth RNAi drug - Alnylam's next-gen hATTR treatment.
Mullard A
Nat Rev Drug Discov; 2022 Aug; 21(8):548-549. PubMed ID: 35794463
[No Abstract] [Full Text] [Related]
34. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
Sanyal AJ; Van Natta ML; Clark J; Neuschwander-Tetri BA; Diehl A; Dasarathy S; Loomba R; Chalasani N; Kowdley K; Hameed B; Wilson LA; Yates KP; Belt P; Lazo M; Kleiner DE; Behling C; Tonascia J;
N Engl J Med; 2021 Oct; 385(17):1559-1569. PubMed ID: 34670043
[TBL] [Abstract][Full Text] [Related]
35. Liver cirrhosis.
Ginès P; Krag A; Abraldes JG; Solà E; Fabrellas N; Kamath PS
Lancet; 2021 Oct; 398(10308):1359-1376. PubMed ID: 34543610
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms and disease consequences of nonalcoholic fatty liver disease.
Loomba R; Friedman SL; Shulman GI
Cell; 2021 May; 184(10):2537-2564. PubMed ID: 33989548
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional factor ATF3 promotes liver fibrosis via activating hepatic stellate cells.
Shi Z; Zhang K; Chen T; Zhang Y; Du X; Zhao Y; Shao S; Zheng L; Han T; Hong W
Cell Death Dis; 2020 Dec; 11(12):1066. PubMed ID: 33311456
[TBL] [Abstract][Full Text] [Related]
38. Osteopontin Takes Center Stage in Chronic Liver Disease.
Song Z; Chen W; Athavale D; Ge X; Desert R; Das S; Han H; Nieto N
Hepatology; 2021 Apr; 73(4):1594-1608. PubMed ID: 32986864
[TBL] [Abstract][Full Text] [Related]
39. MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial.
Sarker D; Plummer R; Meyer T; Sodergren MH; Basu B; Chee CE; Huang KW; Palmer DH; Ma YT; Evans TRJ; Spalding DRC; Pai M; Sharma R; Pinato DJ; Spicer J; Hunter S; Kwatra V; Nicholls JP; Collin D; Nutbrown R; Glenny H; Fairbairn S; Reebye V; Voutila J; Dorman S; Andrikakou P; Lloyd P; Felstead S; Vasara J; Habib R; Wood C; Saetrom P; Huber HE; Blakey DC; Rossi JJ; Habib N
Clin Cancer Res; 2020 Aug; 26(15):3936-3946. PubMed ID: 32357963
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
